Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics

Magdalinou, Nadia; Noyce, Alastair J.; Pinto, Rui; Lindström, Emil; Holmén-Larsson, Jessica; Hölttä, Mikko; Blennow, Kaj; Morris, Huw R.; Skillbäck, Tobias; Warner, Thomas T.; Lees, Andrew J.; Pike, Ian; Ward, Malcolm; Zetterberg, Henrik; Gobom, Johan

doi:10.1016/j.parkreldis.2017.01.016

Cited by 40 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to proteomics layers, a lot of studies were already published studying the proteome in association with PD risk (Halbgebauer et al, 2016 ; Magdalinou et al, 2017 ; Xing et al, 2015 ). Characteristics of the retrieved studies and names of differentially expressed proteins (DEPs) are listed in Supplementary Table S4 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms

Redenšek

Dolžan

Kunej

2018

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Molecular mechanisms of Parkinson's disease (PD) have already been investigated in various different omics landscapes. We reviewed the literature about different omics approaches between November 2005 and November 2017 to depict the main pathological pathways for PD development. In total, 107 articles exploring different layers of omics data associated with PD were retrieved. The studies were grouped into 13 omics layers: genomics–DNA level, transcriptomics, epigenomics, proteomics, ncRNomics, interactomics, metabolomics, glycomics, lipidomics, phenomics, environmental omics, pharmacogenomics, and integromics. We discussed characteristics of studies from different landscapes, such as main findings, number of participants, sample type, methodology, and outcome. We also performed curation and preliminary synthesis of multiple omics data, and identified overlapping results, which could lead toward selection of biomarkers for further validation of PD risk loci. Biomarkers could support the development of targeted prognostic/diagnostic panels as a tool for early diagnosis and prediction of progression rate and prognosis. This review presents an example of a comprehensive approach to revealing the underlying processes and risk factors of a complex disease. It urges scientists to structure the already known data and integrate it into a meaningful context.

show abstract

Section: Resultsmentioning

confidence: 99%

“…They included acute phase/inflammatory markers (increased), neuronal/synaptic markers, and cancer/metastasis formation markers (both decreased). Their levels in PD subjects were intermediate between controls and atypical Parkinsonism (Magdalinou et al, 2017 ).…”

Section: Resultsmentioning

confidence: 99%

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms

Redenšek

Dolžan

Kunej

2018

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

show abstract

“…Instead, higher concentrations were demonstrated in patients with atypical parkinsonism compared to PD patients. 104,105 Furthermore, increased levels were found in PD patients with lower MMSE scores, suggesting the potential role of YKL-40 as biomarker of cognitive impairment in PD. 106 Other studies focusing on CSF biomarkers associated inflammation with cognitive decline in PD.…”

Section: Csf Markers Of Inflammation and Oxidative Stressmentioning

confidence: 96%

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers

et al. 2020

View full text Add to dashboard Cite

Diagnosis of Parkinson’s disease (PD) relies on clinical history and physical examination, but misdiagnosis is common in early stages. Identification of biomarkers for PD may allow for early and more precise diagnosis and provide information about prognosis. Developments in analytical chemistry allow for the detection of a large number of molecules in cerebrospinal fluid (CSF), which are known to be associated with the pathogenesis of PD. Given the pathophysiology of PD, CSF α-synuclein species have the strongest rationale for use, also providing encouraging preliminary results in terms of early diagnosis. In the field of classical Alzheimer’s disease (AD) biomarkers, low CSF Aβ42 levels have shown a robust prognostic value in terms of development of cognitive impairment. Other CSF biomarkers including lysosomal enzymes, neurofilament light chain, markers of neuroinflammation and oxidative stress, although promising, have not proved to be reliable for diagnostic and prognostic purposes yet. Overall, the implementation of CSF biomarkers may give a substantial contribution to the optimal use of disease-modifying drugs.

show abstract

“…We also need to establish whether certain aSyn PTMs can indeed be used as biomarkers of disease, but this requires additional knowledge of their effects (Magdalinou et al, ).…”

Section: Pd Biomarkers Based On Asynmentioning

confidence: 99%

Synucleinopathies: Where we are and where we need to go

Brás

Dominguez-Meijide

Gerhardt

et al. 2020

Journal of Neurochemistry

View full text Add to dashboard Cite

All authors contributed equally to this manuscript. This artic le is relat ed to the Speci al Issue "Synuc lein" Abbreviations: A30P, aSyn substitution of an alanine for a proline at position 30; A53E, aSyn substitution of an alanine for a glutamic acid at position 53; A53T, aSyn substitution of an alanine for a tyrosine at position 53; ALP, autophagy-lysosomal pathway; APLP1, Aβ precursor-like protein 1; aSyn, alpha-synuclein; BiFC, bimolecular fluorescence complementation; CMA, Chaperone-mediated autophagy; CNS, central nervous system; co-IP, co-immunoprecipitation; Cryo-EM, cryo-electron microscopy; CSF, cerebrospinal fluid; Cu, copper; DLB, dementia with Lewy bodies; E46K, aSyn substitution of a glutamic acid for a lysine at position 46; ENS, enteric nervous system; ER, endoplasmic reticulum; Fe, iron; FRET, fluorescence resonance energy transfer; G51D, aSyn substitution of a glycine for a aspartic acid at position 51Abstract Synucleinopathies are a group of disorders characterized by the accumulation of inclusions rich in the a-synuclein (aSyn) protein. This group of disorders includes Parkinson's disease, dementia with Lewy bodies (DLB), multiple systems atrophy, and pure autonomic failure (PAF). In addition, genetic alterations (point mutations and multiplications) in the gene encoding for aSyn (SNCA) are associated with familial forms of Parkinson's disease, the most common synucleinopathy. The Synuclein Meetings are a series that has been taking place every 2 years for about 12 years. The Synuclein Meetings bring together leading experts in the field of Synuclein and related human conditions with the goal of discussing and advancing the research. In 2019, the Synuclein meeting took place in Ofir, a city in the outskirts of Porto, Portugal. The meeting, entitled "Synuclein Meeting 2019:Where we are and where we need to go", brought together >300 scientists studying both clinical and molecular aspects of synucleinopathies. The meeting covered a many of the open questions in the field, in a format that prompted open discussions between the participants, and underscored the need for additional research that, hopefully, will lead to future therapies for a group of as of yet incurable disorders. Here, we provide a summary of the topics discussed in each session and highlight what we know, what we do not know, and what progress needs to be made in order to enable the field to continue to advance. We are confident this systematic assessment of where we stand will be useful to steer the field and contribute to filling knowledge gaps that may form the foundations for future therapeutic strategies, which is where we need to go.

show abstract

Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics

Cited by 40 publications

References 31 publications

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms

From Genomics to Omics Landscapes of Parkinson's Disease: Revealing the Molecular Mechanisms

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers

Synucleinopathies: Where we are and where we need to go

Contact Info

Product

Resources

About